Arrowhead Pharmaceuticals Ownership | Who Owns Arrowhead Pharmaceuticals?


OverviewForecastRevenueFinancialsChartTranscripts

Arrowhead Pharmaceuticals Ownership Summary


Arrowhead Pharmaceuticals is owned by 85.22% institutional investors, 3.76% insiders, and 11.02% retail investors. Blackrock funding, inc. /de is the largest institutional shareholder, holding 12.97% of ARWR shares. iShares Core S&P Small-Cap ETF is the top mutual fund, with 5.41% of its assets in Arrowhead Pharmaceuticals shares.

ARWR Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockArrowhead Pharmaceuticals85.22%3.76%11.02%
SectorHealthcare Stocks 35.38%11.35%53.27%
IndustryBiotech Stocks 33.91%11.39%54.70%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock funding, inc. /de18.16M12.97%$1.14B
Blackrock15.68M12.72%$407.61M
Vanguard group15.29M11.27%$1.02B
Avoro capital advisors10.70M7.64%$670.89M
Fmr7.27M5.19%$455.62M
State street6.50M4.64%$407.31M
Geode capital management4.28M3.06%$274.50M
Fred alger management3.34M2.39%$209.57M
Invesco3.28M2.34%$205.70M
Vestal point capital, lp2.27M1.62%$142.64M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Western financial corp/ca820.24K20.13%$51.43M
Aquilo capital management707.59K20.06%$13.30M
Avoro capital advisors10.70M6.60%$670.89M
Privium fund management b.v.366.94K4.79%$23.01M
M28 capital management lp36.85K4.29%$2.31M
Act capital management82.50K4.07%$5.17M
Vestal point capital, lp2.27M3.99%$142.64M
Wealth effects143.30K3.18%$8.98M
Siren1.62M2.81%$101.29M
Tfg asset management gp127.20K1.55%$7.98M

Top Buyers

HolderShares% AssetsChange
Invesco3.28M0.03%2.73M
Norges bank1.70M0.01%1.70M
Fred alger management3.34M0.92%1.51M
Vestal point capital, lp2.27M3.99%1.38M
Hood river capital management1.06M0.66%1.06M

Top Sellers

HolderShares% AssetsChange
Blackrock funding, inc. /de18.16M0.02%-3.16M
Slate path capital lp---2.52M
Arrowstreet capital, limited partnership587.13K0.02%-1.50M
Rokos capital management llp---939.98K
T. rowe price investment management---822.34K

New Positions

HolderShares% AssetsChangeValue
Norges bank1.70M0.01%1.70M$113.16M
Hood river capital management1.06M0.66%1.06M$66.24M
Renaissance1.04M0.10%1.04M$64.99M
Vanguard fiduciary trust965.77K0.02%965.77K$60.55M
Lord, abbett312.82K0.06%312.82K$19.61M

Sold Out

HolderChange
Financial gravity asset management-4.00
Abound wealth management-8.00
National bank of canada /fi/-10.00
Innealta capital-11.00
Advisornet financial-12.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 20264476.18%119,350,1862.88%851.24%2663.91%1165.45%
Dec 31, 2025134-57.32%23,726,403-78.62%170.27%82-51.19%34-58.54%
Sep 30, 2025128-57.19%25,567,183-75.82%180.32%64-58.97%30-62.50%
Jun 30, 20252936.55%105,554,9492.21%751.29%15119.84%79-2.47%
Mar 31, 2025275-4.84%103,269,2623.49%761.20%128-7.25%80-8.05%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
iShares Core S&P Small-Cap ETF7.47M5.41%-
iShares Core S&P Mid-Cap ETF4.73M3.44%-2.38K
Vanguard Total Stock Mkt Idx Inv4.23M3.02%141.71K
Vanguard US Total Market Shares ETF3.70M2.70%3.98K
iShares Russell 2000 ETF3.18M2.32%26.84K
Vanguard Small Cap Index3.07M2.19%140.75K
Fidelity Growth Compy Commingled Pl S2.92M2.13%149.84K
Fidelity Growth Company Fund2.21M1.58%204.20K
SPDR® S&P Biotech ETF1.73M1.25%3.86K
Vanguard Small Cap Growth Index Inv1.72M1.23%91.86K

Recent Insider Transactions


DateNameRoleActivityValue
May 12, 2026Lu Hongbo-Sell$228.33K
Apr 22, 2026Apel Daniel Joseph Chief Financial OfficerSell$627.86K
Apr 22, 2026Apel Daniel Joseph Chief Financial OfficerSell$81.51K
Apr 22, 2026Apel Daniel Joseph Chief Financial OfficerSell$224.91K
Apr 23, 2026Hamilton James C Chief Medical OfficerSell$750.00K

Insider Transactions Trends


DateBuySell
2026 Q2-5
2026 Q1-22
2025 Q4-36
2025 Q3-4
2025 Q2-5

ARWR Ownership FAQ


Who Owns Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals shareholders are primarily institutional investors at 85.22%, followed by 3.76% insiders and 11.02% retail investors. The average institutional ownership in Arrowhead Pharmaceuticals's industry, Biotech Stocks , is 33.91%, which Arrowhead Pharmaceuticals exceeds.

Who owns the most shares of Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals’s largest shareholders are Blackrock funding, inc. /de (18.16M shares, 12.97%), Blackrock (15.68M shares, 12.72%), and Vanguard group (15.29M shares, 11.27%). Together, they hold 36.96% of Arrowhead Pharmaceuticals’s total shares outstanding.

Does Blackrock own Arrowhead Pharmaceuticals?

Yes, BlackRock owns 12.72% of Arrowhead Pharmaceuticals, totaling 15.68M shares as of Jun 2024. This represents 0.01% of BlackRock's total assets, with a market value of 407.61M$. In the last quarter, BlackRock increased its holdings by 336.57K shares, a 2.19% change.

Who is Arrowhead Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Western financial corp/ca is Arrowhead Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 20.13% of its assets in 820.24K Arrowhead Pharmaceuticals shares, valued at 51.43M$.

Who is the top mutual fund holder of Arrowhead Pharmaceuticals shares?

iShares Core S&P Small-Cap ETF is the top mutual fund holder of Arrowhead Pharmaceuticals shares, with 5.41% of its total shares outstanding invested in 7.47M Arrowhead Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools